Differences in *EGFR* and *KRAS* mutation spectra in lung adenocarcinoma of never and heavy smokers

KAZUYA TAKAMOCHI, SHIAKI OH and KENJI SUZUKI

Department of General Thoracic Surgery, Juntendo University School of Medicine, Bunkyo-ku, Tokyo 113-8431, Japan

Received March 8, 2013; Accepted August 15, 2013

DOI: 10.3892/ol.2013.1551

**Abstract.** Epidermal growth factor receptor (*EGFR*) mutations are common in lung adenocarcinomas of never smokers, while *KRAS* mutations are more frequent among heavy smokers. Different clinicopathological and biological characteristics may, therefore, exist in lung adenocarcinoma according to smoking status. In the present study, a retrospective review was performed using 521 patients with surgically resected lung adenocarcinomas. The clinicopathological factors of age, gender, pathological tumor size, nodal status, lymphatic permeation and blood vessel invasion and the *EGFR* and *KRAS* mutation spectra were compared between never and heavy smokers. *EGFR* mutations were detected in 233 (45%) patients, while *KRAS* mutations were detected in 56 (11%) patients. *EGFR*-mutated adenocarcinomas had a higher prevalence of females in the never smokers compared with the heavy smokers (P<0.001). *KRAS*-mutated adenocarcinomas had a higher prevalence of females (P<0.001) and showed less frequent vascular invasion (P=0.018) in the never smokers compared with the heavy smokers. Minor *EGFR* mutations, excluding exon 21 L858R and exon 19 deletions, were more common in heavy smokers than never smokers (P=0.055). *KRAS* G to A transition was more common in never smokers, while *KRAS* G to T and G to C transversions were more common in heavy smokers (P=0.036). The clinicopathological characteristics and the spectra of the *EGFR* and *KRAS* mutations in lung adenocarcinoma were different between the never and heavy smokers. Further large-scale studies are required to evaluate the efficacy of molecular targeting agents with consideration to specific *EGFR* and *KRAS* mutations.

**Introduction**

In lung cancer, epidermal growth factor receptor (*EGFR*) and *KRAS* mutations occur frequently in adenocarcinoma, rarely in squamous cell carcinoma and hardly ever in small cell carcinoma (1-3). These two mutations are known to have different correlations with smoking exposure. Specifically, *EGFR*-mutated adenocarcinomas are more common in individuals who have never smoked (1,3), while *KRAS*-mutated adenocarcinomas occur more frequently among heavy smokers (4). Therefore, we hypothesized that there may be different biological characteristics and etiologies between these types of lung adenocarcinomas related to cumulative exposure to tobacco smoke.

The presence of an *EGFR* mutation is the most important predictor of the efficacy of *EGFR* tyrosine kinase inhibitors (TKIs), such as gefitinib and erlotinib (5,6). Activating mutations in the TK domain of *EGFR* are limited to exons 18-21, but show marked structural diversity, including point mutations, deletions and insertions (1,3,5,6). The L858R in exon 21 and small deletions in exon 19 have been shown to account for 80-90% of all *EGFR* mutations and are often termed as classic activating mutations (3). Although an inverse correlation between the extent of smoking and the frequency of these mutations has been shown by a number of investigators (7,8), the correlation between smoking exposure and other minor mutations remains unclear.

*KRAS*-mutated lung adenocarcinomas are more predominant in Caucasians (~30%) than East Asians (~10%) (1). These mutations serve as a useful biomarker of resistance to *EGFR-TKIs* (9), occurring frequently at codon 12 and occasionally at codon 13, but rarely located at codon 61 (2). Several organ-specific *KRAS* mutation genotypes have been reported. The majority are G to T transversions in lung adenocarcinoma and G to A transitions in colorectal cancer (10). Although there have been few studies investigating the correlation between smoking exposure and *KRAS* mutation genotypes, Miller et al (11) reported that never smokers were significantly more likely than former or current smokers to have G to A transition mutations than G to T or G to C transversion mutations.

The purpose of the present study was to elucidate the differences in the clinicopathological characteristics of *EGFR*- and *KRAS*-mutated lung adenocarcinomas and their related mutation spectra between never smokers and heavy smokers.
Materials and methods

Patients. Between February 2009 and March 2012, 667 patients with primary lung cancer underwent pulmonary resection. Among these, 521 patients with adenocarcinoma were selected for retrospective review and examined for \textit{EGFR} and \textit{KRAS} mutations using surgically resected specimens. There were 277 (53\%) never smokers (≤5 pack-years), 53 (10\%) light smokers (5-20 pack-years) and 191 (37\%) heavy smokers (>20 pack-years). Induction chemotherapy, radiotherapy and pre-operative treatment with \textit{EGFR}-TKIs were not performed for any of the patients in this series.

This study was conducted on specimens stored in the tissue bank, with the approval of the Institutional Review Board (IRB) of Juntendo University School of Medicine (Tokyo, Japan). According to the tissue bank protocol, in order to collect specimens for studies gaining approval by the IRB in the future, written consent was obtained from patients prior to surgery for the collection and storage of specimens during surgery. The contents of this study were deemed ethically acceptable and the IRB approved the use of the specimens stored in the tissue bank without obtaining new informed consent.

Molecular analysis. Genomic DNA was extracted from 3-5-mm\textsuperscript{3} cubes of frozen fresh lung cancer tissue samples from surgically resected specimens. The peptide nucleic acid-locked nucleic acid (PNA-LNA) polymerase chain reaction (PCR) clamp method (12) was used to identify \textit{EGFR} mutations: G719A, G719C and G719A in exon 18; all deletion genotypes in exon 19; T790M in exon 20; and L858R and L861Q in exon 21. The PNA-mediated PCR clamping method (13) was used to identify \textit{KRAS} mutations: All genotypes at codon 12 and 13.

\textbf{Table I. Clinicopathological characteristics according to \textit{EGFR} and \textit{KRAS} mutation status in patients with lung adenocarcinomas.}

| Characteristics          | \textit{EGFR}/\textit{KRAS} wild-type (n=232) | \textit{EGFR} mutant (n=233) | \textit{KRAS} mutant (n=56) | P-value\textsuperscript{a} |
|--------------------------|---------------------------------------------|-------------------------------|-----------------------------|--------------------------|
| Age, years               | 64 (24-86)                                  | 67 (35-88)                   | 69 (44-87)                  | 0.213\textsuperscript{b}  |
| Gender, n (%)            |                                             |                               |                             | <0.001\textsuperscript{c} |
| Male                     | 124 (53)                                    | 81 (35)                      | 40 (71)                     |                          |
| Female                   | 108 (47)                                    | 152 (65)                     | 16 (29)                     |                          |
| Smoking status, n (%)    |                                             |                               |                             | <0.001\textsuperscript{c} |
| Never smoker             | 111 (48)                                    | 155 (67)                     | 11 (20)                     |                          |
| Smoker                   | 121 (52)                                    | 78 (33)                      | 45 (80)                     |                          |
| Tumor size, mm           | 23 (2-85)                                   | 24 (5-115)                   | 29 (7-105)                  | 0.072\textsuperscript{b}  |
| Pathological nodal status, n (%) | 180 (78)                                      | 194 (83)                     | 43 (77)                     | 0.257\textsuperscript{c}  |
| N0                       | 52 (22)                                     | 39 (17)                      | 13 (23)                     |                          |
| N1/N2                    |                                             |                               |                             | 0.644\textsuperscript{c}  |
| Lymphatic permeation, n (%) | 84 (36)                                        | 74 (32)                      | 16 (29)                     |                          |
| Positive                 | 148 (64)                                    | 159 (68)                     | 40 (71)                     | 0.448\textsuperscript{c}  |
| Negative                 | 84 (36)                                     | 71 (30)                      | 20 (36)                     |                          |
| Vascular invasion, n (%) |                                             |                               |                             |                          |
| Positive                 | 148 (64)                                    | 162 (70)                     | 36 (64)                     |                          |

\textsuperscript{a}P-values were derived from a comparison between \textit{EGFR} and \textit{KRAS} mutants; \textsuperscript{b}t-test; \textsuperscript{c}$\chi^2$ test. \textit{EGFR}, epidermal growth factor receptor.

Results

\textit{EGFR} and \textit{KRAS} mutations in all adenocarcinoma patients. \textit{EGFR} and \textit{KRAS} mutations were detected in 233 (45\%) and 56 (11\%) of the total 521 lung adenocarcinoma patients, respectively. These two mutations were mutually exclusive. The point mutation L858R in exon 21 and deletions in exon 19 were detected in 118 and 98 tumors, respectively, and together, they accounted for 93\% of all \textit{EGFR} alterations. The remaining minor \textit{EGFR} mutations included exon 18 G719A in eight tumors, exon 18 G719S in three tumors, exon 18 G719C in three tumors, exon 21 L861Q in four tumors and exon 20 T790M in four tumors. Double mutations were identified in

\textit{EGFR} and \textit{KRAS} mutations in never smokers. Among never smokers (≤5 pack-years), 155 (67\%) of 233 \textit{EGFR} mutants were detected, compared with 111 (48\%) of 232 wild-type samples, and the difference was statistically significant (P<0.001; \textit{t}-test). Among never smokers, 11 (20\%) of 56 \textit{KRAS} mutants were detected, compared with 15 (7\%) of 227 wild-type samples, and the difference was also statistically significant (P<0.001; \textit{t}-test). A similar difference was observed between never and heavy smokers (P<0.001; \textit{t}-test).

\textit{EGFR} and \textit{KRAS} mutations in light smokers. The difference in the \textit{EGFR} and \textit{KRAS} mutation rate between light smokers (5-20 pack-years) and never smokers was not statistically significant (P=0.140; \textit{t}-test for \textit{EGFR}, and P=0.090; \textit{t}-test for \textit{KRAS}).

\textit{EGFR} and \textit{KRAS} mutations in heavy smokers. Among heavy smokers (>20 pack-years), 45 (80\%) of 56 \textit{KRAS} mutants were detected, compared with 15 (7\%) of 227 wild-type samples, and the difference was statistically significant (P<0.001; \textit{t}-test). No statistical difference was observed between heavy smokers and never smokers (P=0.563; \textit{t}-test for \textit{EGFR}, and P=0.080; \textit{t}-test for \textit{KRAS}).

\textit{EGFR} and \textit{KRAS} mutations in never smokers and heavy smokers. Among never smokers and heavy smokers, 118 (51%) of 233 \textit{EGFR} mutants were detected, compared with 45 (80\%) of 56 \textit{KRAS} mutants, and the difference was statistically significant (P<0.001; \textit{t}-test).
four tumors: Exon 21 L858R and exon 19 deletion in one tumor, exon 21 L861Q and exon 20 T790M in one tumor and exon 21 L858R and exon 20 T790M in two tumors. Notably, exon 20 T790M, which has been recognized as a mutation that confers resistance to EGFR-TKIs, was always coupled with other point mutations. With regard to KRAS, point mutations in codon 12 were observed in 54 (96%) tumors, and point mutations in codon 13 were detected in two (4%) tumors. G to T or G to C transversions were identified in 43 (77%) tumors, and G to A transition was observed in 13 (23%) tumors.

The clinicopathological characteristics based on EGFR and KRAS mutation status are summarized in Table I. EGFR-mutated adenocarcinomas were more common in female never smokers than KRAS mutations.

**Table II. Patient characteristics for EGFR-mutated lung adenocarcinomas according to smoking status.**

| Characteristics | Never smoker (n=155) | Light smoker (n=25) | Heavy smoker (n=53) | P-value\(^a\) |
|-----------------|---------------------|---------------------|---------------------|--------------|
| Age, years | 67 (35-88) | 66 (37-85) | 67 (48-86) | 0.912\(^b\) |
| Gender, n (%) | 26 (17) | 15 (60) | 40 (75) | <0.001\(^c\) |
| Male | 129 (83) | 10 (40) | 13 (25) | 0.383\(^b\) |
| Female | 24 (5-115) | 23 (7-68) | 22 (5-60) | 0.972\(^c\) |
| Tumor size, mm | 129 (83) | 21 (84) | 44 (83) | 0.221\(^c\) |
| Pathological nodal status, n (%) | 19 (12) | 16 (64) | 40 (75) | 0.944\(^c\) |
| N0 | 52 (34) | 9 (36) | 13 (25) | 0.633\(^c\) |
| N1/N2 | 103 (67) | 16 (64) | 40 (75) | 0.535\(^c\) |
| Positive | 46 (30) | 9 (36) | 16 (30) | 0.055\(^d\) |
| Negative | 109 (70) | 16 (64) | 37 (70) | 0.055\(^d\) |
| Vascular invasion, n (%) | 79 (51) | 14 (56) | 25 (47) | 0.633\(^c\) |
| Exon 21 L858R, n (%) | 76 (49) | 11 (44) | 28 (53) | 0.535\(^c\) |
| Positive | 69 (45) | 8 (32) | 21 (40) | 0.055\(^d\) |
| Negative | 86 (55) | 17 (68) | 32 (60) | 0.055\(^d\) |
| Minor mutations, n (%) | 8 (5) | 3 (12) | 7 (13) | 0.055\(^d\) |
| Positive | 147 (95) | 22 (88) | 46 (87) | 0.055\(^d\) |

\(^a\)P-values were derived from a comparison between never and heavy smokers; \(^b\)t-test; \(^c\)χ² test; \(^d\)Fisher’s exact test. EGFR, epidermal growth factor receptor.

EGFR mutations were detected in 115 (67%) never smokers, 25 (11%) light smokers and 53 (23%) heavy smokers (Table II). EGFR-mutated adenocarcinomas had a higher female prevalence in never smokers compared with that in heavy smokers (P<0.001). Minor EGFR mutations, which exclude exon 21 L858R and exon 19 deletions, were more frequent in heavy smokers than in never smokers. However, this difference was not statistically significant (P=0.055).

**KRAS mutations** were detected in 11 (20%) never smokers, 8 (14%) light smokers and 37 (66%) heavy smokers (Table III). **KRAS-mutated adenocarcinomas** had a higher prevalence in females (P<0.001) and showed less frequent vascular invasion (P=0.018) in never smokers compared with heavy smokers. G to A transition was more common in never smokers, while G to T and G to C transversions were more common in heavy smokers (P=0.036).

**Gender differences in the characteristics of EGFR- and KRAS-mutated lung adenocarcinomas.** There were no significant gender differences in age, pathological nodal status, lymphatic permeation, blood vessel invasion or mutation spectra for either EGFR- or KRAS-mutated lung adenocarcinomas (Tables IV and V). The mean tumor size of the EGFR-mutated adenocarcinomas was significantly larger in males compared with females (P=0.027; Table IV). However, the corresponding gender difference was not significant for KRAS-mutated adenocarcinoma (P=0.802; Table V).
Tobacco smoking is the main cause of lung cancer worldwide. Despite this, ~25% of worldwide (14) and 30-40% of Asian lung cancer patients (15) have never smoked. The occurrence of EGFR and KRAS mutations has been reported to be associated with smoking status. EGFR mutations are more commonly identified in the adenocarcinomas of never smokers (1,3), while KRAS mutations are more frequent in heavy smokers (4). Although no carcinogens causing EGFR or KRAS mutations in never smokers have yet been identified, the causes of each are suspected to differ based on smoking status. The present study showed notable differences in the clinicopathological characteristics and mutation spectra of lung adenocarcinoma based on cumulative exposure to tobacco smoke.

It is noteworthy that minor EGFR mutations, which exclude exon 21 L858R and exon 19 deletions, tended to be more common in heavy smokers than in never smokers. However, it remains unclear why the incidence of exon 21 L858R and exon 19 deletions is so much higher than the various other TK domain mutations of EGFR (1,3). There should be specific mutagens (other than those associated with smoking) associated with these classic activating EGFR mutations. By contrast, the minor mutations of EGFR may randomly occur due to carcinogens present in tobacco smoke.

The correlation between EGFR-TKI efficacy and minor mutations is not fully clear. An in vitro study showed that gefitinib had variable growth-suppressive effects for different EGFR mutant-expressing cells (16). In a previous study of 62 lung cancer patients with minor EGFR mutations, Wu et al (17) observed a favorable response to EGFR-TKIs in 28 patients with point mutations on G719 and L861 and a poor response in 34 patients with different mutations. De Pas et al (18) also observed different antitumor activities of EGFR-TKIs according to the specific EGFR mutation genotype in a study of 10 lung cancer patients with minor mutations. The efficacy of EGFR-TKI treatment in patients with minor mutations is diverse and depends on the specific EGFR mutation.

KRAS and TP53 mutations in lung cancer have been reported to occur more frequently in smokers than in never smokers (4,19). Fewer studies have investigated mutation spectrum variations for KRAS according to smoking status than TP53 mutations, yet similar correlations between the two have been reported (19-21). Specifically, G to T transition is most common in lung cancers in smokers, while G to A transition is more frequent among never smokers. Riely et al (21) demonstrated that not only G to T, but also G to C transition frequently occurs in smokers with KRAS-mutated lung adenocarcinomas. The results of the current study are in agreement with these previous observations.
The association between KRAS mutation and the lack of benefit of anti-EGFR monoclonal antibodies, such as cetuximab and panitumumab, in metastatic colorectal cancer has been established (22). By contrast, for advanced non-small cell lung cancer, the benefit of cetuximab has been shown regardless of KRAS mutation status in a phase III trial of cisplatin and vinorelbine treatment, with or without cetuximab (23,24). Notably, the KRAS mutation spectrum in colorectal cancer is quite different from that in lung cancer of smokers; G to T transversion is most common in lung cancer, while G to A transition is most common in colorectal cancer (10). The KRAS mutation spectrum may therefore be a better determinant of anti-EGFR monoclonal antibody efficacy than simply the presence or absence of the KRAS mutation. G to A transition is frequent not only in colorectal cancer, but also in lung cancer of never smokers, indicating that the same mutagen may be associated with their carcinogenic processes.

Gender differences in lung cancer susceptibility have been previously reported. Several studies have provided evidence for a biological role of estrogen in lung carcinogenesis by direct promotion of cell proliferation (25,26). Environmental risk factors including indoor air pollution from cooking-oil fumes (27) and coal burning (28) have been reportedly associated with high lung cancer incidence among Chinese women. However, in the present study, no gender differences were observed in the characteristics of the EGFR- or KRAS-mutated lung adenocarcinomas other than tumor size, indicating that smoking status has a greater effect on the cause of lung adenocarcinoma than gender differences in Japanese patients.

In conclusion, in the present study, the clinicopathological characteristics and the spectra of EGFR and KRAS mutations in lung adenocarcinoma were different between never and heavy smokers. These findings indicate that the causes of these mutations in lung adenocarcinomas are different in never and heavy smokers. The efficacy of molecular targeting agents may differ based on the mutation spectra of the targeted genes. Therefore, in the future, the efficacy of these agents should be evaluated based not only on the presence of the corresponding gene mutation in an individual tumor, but also on the specific mutation spectrum of each gene. Further large-scale studies are recommended to further investigate and validate these spectra.

Acknowledgements

This study was supported in part by a Grant-in-Aid for the Cancer Research from the Ministry of Health, Labour and Welfare of Japan and the Smoking Research Foundation.
EGFR mutations in lung cancer. Use of cigarette smoking - frequency and molecular characteristics of bronchioloalveolar carcinoma subtype, predict response to epidermal growth factor receptor-tyrosine kinase inhibitors in patients with non-small-cell lung cancer harboring rare epidermal growth factor receptor mutations.

Chen YR, Fu YN, Lin CH, et al: Distinctive activation patterns in constitutively active and gefitinib-sensitive EGFR mutants. Oncogene 25: 1205-1215, 2006.

Wu YJ, Yu CJ, Chang YC, Yang CH, Shih YJ and Yang PC: Effectiveness of tyrosine kinase inhibitors on ‘uncommon’ epidermal growth factor receptor mutations of unknown clinical significance in non-small cell lung cancer. Clin Cancer Res 17: 3812-3821, 2011.

De Pas T, Toffalorio F, Manzotti M, et al: Activity of epidermal growth factor receptor-tyrosine kinase inhibitors in patients with non-small cell lung cancer harboring rare epidermal growth factor receptor mutations. J Thorac Oncol 6: 1895-1901, 2011.

Bennett WP, Hussain SP, Vahakangas KH, Khan MA, Shields PG and Harris CC: Molecular epidemiology of human cancer risk: gene-environment interactions and p53 mutation spectrum in human lung cancer. J Pathol 187: 8-18, 1999.

Le Calvez F, Mukeria A, Hunt JD, et al: TP53 and KRAS mutation load and types in lung cancers in relation to tobacco smoke: distinct patterns in never, former, and current smokers. Cancer Res 65: 5076-5083, 2005.

Riely GJ, Kris MG, Rosenbaum D, et al: Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma. Clin Cancer Res 14: 5731-5734, 2008.

Allegra CJ, Jessup JM, Somerfield MR, et al: American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol 27: 2091-2096, 2009.

O’Byrne KJ, Gatzeumeier U, Bondarenko I, et al: Molecular biomarkers in non-small-cell lung cancer: a retrospective analysis of data from the phase 3 FLEX study. Lancet Oncol 12: 795-805, 2011.

Pirker R, Pereira JR, Szczesna A, et al: Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet 373: 1525-1531, 2009.

Mollerup S, Jorgensen K, Berge G and Haugen A: Expression of estrogen receptors alpha and beta in human lung tissue and cell lines. Lung Cancer 37: 153-159, 2002.

Stabile LP, Davis AL, Gubish CT, et al: Estrogen receptors alpha and beta in human lung tissue and cell lines. Lung Cancer 37: 153-159, 2002.

Yu IT, Chiu YL, Au JS, Wong TW and Tang JL: Dose-response relationship between cooking fumes exposures and lung cancer among Chinese nonsmoking women. Cancer Res 66: 4961-4967, 2006.

Kleinerman RA, Wang Z, Wang L, et al: Lung cancer and indoor exposure to coal and biomass in rural China. J Occup Environ Med 44: 338-344, 2002.

References

1. Shigematsu H, Lin L, Takahashi T, et al: Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 97: 339-346, 2005.

2. Rodenhuis S, van de Wetering ML, Mooi WJ, Evers SG, van Zandwijk N and Bos JL: Mutational activation of the K-ras oncogene. A possible pathogenetic factor in adenocarcinoma of the lung. N Engl J Med 317: 929-935, 1987.

3. Chan SK, Gullick WJ and Hill ME: Mutations of the epidermal growth factor receptor in non-small cell lung cancer - search and destroy. Eur J Cancer 42: 17-23, 2006.

4. Ahrendt SA, Decker PA, Alawi EA, et al: Cigarette smoking is strongly associated with mutation of the K-ras gene in patients with primary adenocarcinoma of the lung. Cancer 92: 1525-1530, 2001.

5. Lynch TJ, Bell DW, Sordella R, et al: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350: 2129-2139, 2004.

6. Paez JG, Janne PA, Lee JC, et al: EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304: 1497-1500, 2004.

7. Pham D, Kris MG, Riely GJ, et al: Use of cigarette-smoking history to estimate the likelihood of mutations in epidermal growth factor receptor gene exons 19 and 21 in lung adenocarcinomas. J Clin Oncol 24: 1700-1704, 2006.

8. Sugio K, Uramoto H, Ono K, et al: Mutations within the tyrosine kinase domain of EGFR gene specifically occur in lung adenocarcinoma patients with a low exposure of tobacco smoking. Br J Cancer 94: 896-903, 2006.

9. Pao W, Wang TY, Riely GJ, et al: KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med 2: e17, 2005.

10. Bos JL: ras oncogenes in human cancer: a review. Cancer Res 49: 4682-4689, 1989.

11. Miller VA, Riely GJ, Zakowski MF, et al: Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib. J Clin Oncol 26: 1472-1478, 2008.

12. Nagai Y, Miyazawa H, Huqun, et al: Genetic heterogeneity of the epidermal growth factor receptor in non-small cell lung cancer cell lines revealed by a rapid and sensitive detection system, the peptide nucleic acid-locked nucleic acid PCR clamp. Cancer Res 65: 7276-7282, 2005.

13. Thiede C, Bayerdorffer E, Blassczyk R, Wittig B and Neubauer A: Simple and sensitive detection of mutations in the ras proto-oncogenes using PNA-mediated PCR clamping. Nucleic Acids Res 24: 983-984, 1996.

14. Ferlay J, Shin HR, Bray F, Forman D, Mathers C and Parkin DM: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127: 2893-2917, 2010.

15. Moh CK, Gao F, Lim WT, et al: Never-smokers with lung cancer: epidemiologic evidence of a distinct disease entity. J Clin Oncol 24: 2245-2251, 2006.